Skip to main content

Gene Therapy for Sickle Cell Disease Likely Cost-Effective at

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 23, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Jan. 22, 2024 -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published online Jan. 23 in the Annals of Internal Medicine.

Anirban Basu, Ph.D., from The Comparative Health Outcomes, Policy & Economics Institute at the University of Washington in Seattle, and colleagues examined the cost-effectiveness of gene therapy for SCD and its value-based prices in a comparative modeling analysis conducted across two independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) among persons eligible for gene therapy.

The researchers estimated incremental cost-effectiveness ratios of $193,000 and $427,000 per quality-adjusted life year (QALY) with UW-MEASURE and FH-HISCORE, respectively, under the health care sector perspective, and at an assumed $2 million price for gene therapy. From the societal perspective, the corresponding estimates were $126,000 and $281,000 per QALY. Acceptable value-based prices ranged from $1 million to $2.5 million from a societal perspective, depending on the use of alternative effective metrics or equity-informed threshold values. The results were sensitive to costs of myeloablative conditioning before gene therapy, the effect on caregiver quality of life, and the impact of gene therapy on long-term survival.

"Our results suggest that gene therapy for SCD can bring substantial benefits to this population and provide evidence for the proper reimbursement level for these therapies by Centers for Medicare & Medicaid Services," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Read this next

Active Surveillance Effective Strategy for Favorable-Risk Prostate Cancer

FRIDAY, May 31, 2024 -- Active surveillance is an effective management strategy for men with favorable-risk prostate cancer, with an estimated rate of metastasis of 1.4 percent at...

Longer Transfer Gap to Adult Care Increases Inpatient Encounters in Sickle Cell Disease

FRIDAY, May 31, 2024 -- For young adults (YAs) with sickle cell disease (SCD), a longer transfer gap is associated with increased inpatient encounters and decreased outpatient...

BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults

FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.